Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center
https://doi.org/10.21518/2079-701X-2019-19-16-21
Abstract
About the Authors
K. K. LaktionovRussian Federation
Dr. of Sci. (Med), Professor, Head of the Department of Chemotherapy No.1 of the Thoraco-Abdominal Department
23, Kashirskoye sh., Moscow, 115478, Russia
K. A. Sarantseva
Russian Federation
Cand. of Sci. (Med), Oncologist
23, Kashirskoye sh., Moscow, 115478, Russia
D. I. Yudin
Russian Federation
Cand. of Sci. (Med), Senior Researcher
23, Kashirskoye sh., Moscow, 115478, Russia
V. V. Breder
Russian Federation
Dr. of Sci. (Med), Leading Researcher
23, Kashirskoye sh., Moscow, 115478, Russia
E. V. Reutova
Russian Federation
Cand. of Sci. (Med), Senior Researcher
23, Kashirskoye sh., Moscow, 115478, Russia
K. P. Laktionov
Russian Federation
Dr. of Sci. (Med), Professor, Leading Researcher
23, Kashirskoye sh., Moscow, 115478, Russia
References
1. Gettinger S., Horn L., Jackman D. at al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology 2018;36(17):JCO2017770412.·doi: 10.1200/JCO.2017.77.0412.
2. Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: TwoYear Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-3933. doi:. 10.1200/JCO.2017.74.3062
3. Reck M., Taylor F., Penrod J.R., DeRosa M., Morrissey L., Dastani H., Orsini L., Gralla R.J. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study. J Thorac Oncol. 201813(2):194-204. doi: 10.1016/j.jtho.2017.10.029.
4. Laktionov, K.K., Sarantseva K.A., Breder V.V., Reutova E.V., Yudin D.I., Laktionova L.V. Results of nivolumab use in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Cancer Research Center. Voprosy oncologii = Problems in oncology2017;63(5):724-728. (In Russ.)
5. Laktionov K.K., Sarantseva K.A., Breder V.V., Okruzhnova M.A., Peregudova M.V. Immunotherapy for non-small cell lung cancer treatment. Zlokachestvennye opukholi = Malignant tumours. 2016;(3):17-24. (In Russ.) doi: 10.18027/2224-5057-2016-3-17-24.
6. Burstein H.J., Krilov L., Aragon-Ching J.B., Baxter N.N., Chiorean E.G., Chow W.A. et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292.
7. Chae Y.K., Pan A., Davis A.A., Raparia K., Mohindra N.A., Matsangou M., Giles F.J. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cacer:Is PD-L1 Expression a Good Marker for Patient Selection? Clin Lung Cancer. 2016;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011.
Review
For citations:
Laktionov KK, Sarantseva KA, Yudin DI, Breder VV, Reutova EV, Laktionov KP. Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. Meditsinskiy sovet = Medical Council. 2019;(19):16-21. (In Russ.) https://doi.org/10.21518/2079-701X-2019-19-16-21